PDB Short entry for 2BXQ HEADER TRANSPORT PROTEIN 26-JUL-05 2BXQ TITLE HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE, PHENYLBUTAZONE AND TITLE 2 INDOMETHACIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: SERUM ALBUMIN; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: HUMAN SERUM ALBUMIN; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 TISSUE: PLASMA; SOURCE 6 EXPRESSION_SYSTEM: PICHIA PASTORIS; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 4922 KEYWDS TRANSPORT PROTEIN, ALBUMIN, CARRIER PROTEIN, LIPID-BINDING, METAL- KEYWDS 2 BINDING, DRUG- BINDING, MYRISTATE, PHENYLBUTAZONE, INDOMETHACIN EXPDTA X-RAY DIFFRACTION AUTHOR J.GHUMAN,P.A.ZUNSZAIN,I.PETITPAS,A.A.BHATTACHARYA,S.CURRY REVDAT 4 13-DEC-23 2BXQ 1 REMARK REVDAT 3 24-FEB-09 2BXQ 1 VERSN REVDAT 2 20-DEC-06 2BXQ 1 JRNL REVDAT 1 22-SEP-05 2BXQ 0 JRNL AUTH J.GHUMAN,P.A.ZUNSZAIN,I.PETITPAS,A.A.BHATTACHARYA,M.OTAGIRI, JRNL AUTH 2 S.CURRY JRNL TITL STRUCTURAL BASIS OF THE DRUG-BINDING SPECIFICITY OF HUMAN JRNL TITL 2 SERUM ALBUMIN. JRNL REF J.MOL.BIOL. V. 353 38 2005 JRNL REFN ISSN 0022-2836 JRNL PMID 16169013 JRNL DOI 10.1016/J.JMB.2005.07.075 REMARK 2 REMARK 2 RESOLUTION. 2.60 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : MLF REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.60 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 22.30 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1667036.560 REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.3 REMARK 3 NUMBER OF REFLECTIONS : 20764 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.196 REMARK 3 FREE R VALUE : 0.256 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.600 REMARK 3 FREE R VALUE TEST SET COUNT : 959 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.008 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.60 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.76 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 3282 REMARK 3 BIN R VALUE (WORKING SET) : 0.2890 REMARK 3 BIN FREE R VALUE : 0.3540 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.40 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 152 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.029 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4468 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 163 REMARK 3 SOLVENT ATOMS : 27 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 54.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 52.00 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 11.45000 REMARK 3 B22 (A**2) : 0.43000 REMARK 3 B33 (A**2) : -11.88000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 6.68000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.31 REMARK 3 ESD FROM SIGMAA (A) : 0.37 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.42 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.45 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 18.80 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.810 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : GROUP REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.32 REMARK 3 BSOL : 53.59 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : P1Z.SC.PAR REMARK 3 PARAMETER FILE 3 : IMN.PAR REMARK 3 PARAMETER FILE 4 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 5 : MYR.PAR REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : P1Z.SC.TOP REMARK 3 TOPOLOGY FILE 3 : MYR.TOP REMARK 3 TOPOLOGY FILE 4 : IMN.TOP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2BXQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 26-JUL-05. REMARK 100 THE DEPOSITION ID IS D_1290025071. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-MAY-02 REMARK 200 TEMPERATURE (KELVIN) : 298.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX9.6 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.87 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 20764 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.600 REMARK 200 RESOLUTION RANGE LOW (A) : 22.300 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.6 REMARK 200 DATA REDUNDANCY : 3.000 REMARK 200 R MERGE (I) : 0.05000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 13.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.60 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.74 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.4 REMARK 200 DATA REDUNDANCY IN SHELL : 3.00 REMARK 200 R MERGE FOR SHELL (I) : 0.36000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: PDB ENTRY 1E7G REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 52.21 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.59 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 7.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 94.12500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 19.41200 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 94.12500 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 19.41200 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ASP A 1 REMARK 465 ALA A 2 REMARK 465 LEU A 585 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 4 CE NZ REMARK 470 LYS A 41 CE NZ REMARK 470 GLU A 48 CD OE1 OE2 REMARK 470 GLU A 82 CG CD OE1 OE2 REMARK 470 GLN A 94 CG CD OE1 NE2 REMARK 470 ASP A 108 CG OD1 OD2 REMARK 470 ASN A 109 CG OD1 ND2 REMARK 470 ASN A 111 CG OD1 ND2 REMARK 470 GLU A 119 CD OE1 OE2 REMARK 470 ARG A 160 CZ NH1 NH2 REMARK 470 LYS A 162 CE NZ REMARK 470 GLN A 170 CD OE1 NE2 REMARK 470 LYS A 190 CE NZ REMARK 470 GLN A 204 CG CD OE1 NE2 REMARK 470 LYS A 205 CD CE NZ REMARK 470 GLU A 227 CD OE1 OE2 REMARK 470 LYS A 240 CE NZ REMARK 470 GLU A 244 CD OE1 OE2 REMARK 470 LYS A 276 CG CD CE NZ REMARK 470 GLU A 294 CD OE1 OE2 REMARK 470 ASP A 301 CG OD1 OD2 REMARK 470 LYS A 313 CB CG CD CE NZ REMARK 470 LYS A 359 CD CE NZ REMARK 470 LYS A 372 CG CD CE NZ REMARK 470 LYS A 389 CB CG CD CE NZ REMARK 470 GLN A 390 CD OE1 NE2 REMARK 470 GLU A 396 CG CD OE1 OE2 REMARK 470 LYS A 432 CE NZ REMARK 470 LYS A 436 CD CE NZ REMARK 470 LYS A 439 CG CD CE REMARK 470 LYS A 444 CG CD CE NZ REMARK 470 GLN A 459 CD OE1 NE2 REMARK 470 LYS A 475 CE NZ REMARK 470 GLU A 495 CG CD OE1 OE2 REMARK 470 LYS A 500 CD CE NZ REMARK 470 GLU A 505 CG CD OE1 OE2 REMARK 470 ILE A 513 CD1 REMARK 470 LEU A 516 CB CG CD1 CD2 REMARK 470 LYS A 519 CG CD CE NZ REMARK 470 LYS A 524 CG CD CE NZ REMARK 470 GLU A 542 CG CD OE1 OE2 REMARK 470 LYS A 545 CE NZ REMARK 470 GLU A 556 CG CD OE1 OE2 REMARK 470 LYS A 557 CD CE NZ REMARK 470 LYS A 560 CD CE NZ REMARK 470 ASP A 563 CG OD1 OD2 REMARK 470 THR A 566 CB OG1 CG2 REMARK 470 GLU A 570 CG CD OE1 OE2 REMARK 470 LYS A 573 CB CG CD CE NZ REMARK 470 LYS A 574 CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TYR A 30 -63.76 -93.25 REMARK 500 ASN A 61 -6.42 54.92 REMARK 500 ASN A 130 67.70 179.25 REMARK 500 CYS A 169 2.63 -69.46 REMARK 500 ASP A 173 79.01 -113.96 REMARK 500 LYS A 205 -78.32 -54.59 REMARK 500 PHE A 223 62.24 -118.28 REMARK 500 ILE A 271 -53.10 -126.00 REMARK 500 LEU A 283 -35.95 -38.33 REMARK 500 PRO A 303 -176.26 -48.29 REMARK 500 ALA A 322 79.00 -160.88 REMARK 500 ALA A 364 -72.02 -44.07 REMARK 500 GLN A 397 -81.38 -61.36 REMARK 500 THR A 467 64.44 -118.64 REMARK 500 VAL A 469 -35.17 -139.64 REMARK 500 TYR A 497 137.52 -33.08 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 MYR A 1003 REMARK 610 MYR A 1004 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A1001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A1002 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A1003 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A1004 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A1005 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A1006 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IMN A2001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE P1Z A2002 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IMN A2003 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AO6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN REMARK 900 RELATED ID: 1BJ5 RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID REMARK 900 RELATED ID: 1BKE RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN IN A COMPLEX WITH MYRISTIC ACID AND TRI- REMARK 900 IODOBENZOIC ACID REMARK 900 RELATED ID: 1BM0 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN REMARK 900 RELATED ID: 1E78 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN REMARK 900 RELATED ID: 1E7A RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN COMPLEXED WITH THE GENERAL REMARK 900 ANESTHETIC PROPOFOL REMARK 900 RELATED ID: 1E7B RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN COMPLEXED WITH HALOTHANE REMARK 900 RELATED ID: 1E7C RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE GENERAL REMARK 900 ANESTHETIC HALOTHANE REMARK 900 RELATED ID: 1E7E RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH DECANOIC ACID REMARK 900 RELATED ID: 1E7F RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH DODECANOIC ACID REMARK 900 RELATED ID: 1E7G RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID REMARK 900 RELATED ID: 1E7H RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH HEXADECANOIC ACID REMARK 900 RELATED ID: 1E7I RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH OCTADECANOIC ACID REMARK 900 RELATED ID: 1GNI RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH CIS-9- OCTADECENOIC ACID (OLEIC REMARK 900 ACID) REMARK 900 RELATED ID: 1GNJ RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH CIS-5,8 ,11,14-EICOSATETRAENOIC REMARK 900 ACID (ARACHIDONIC ACID) REMARK 900 RELATED ID: 1H9Z RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE R-(+) REMARK 900 ENANTIOMER OF WARFARIN REMARK 900 RELATED ID: 1HA2 RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE S-(-) REMARK 900 ENANTIOMER OF WARFARIN REMARK 900 RELATED ID: 1HK1 RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L- REMARK 900 THYRONINE) REMARK 900 RELATED ID: 1HK2 RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5' REMARK 900 -TETRAIODO-L- THYRONINE) REMARK 900 RELATED ID: 1HK3 RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5' REMARK 900 -TETRAIODO-L- THYRONINE) REMARK 900 RELATED ID: 1HK4 RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L- REMARK 900 THYRONINE) AND MYRISTIC ACID (TETRADECANOIC ACID) REMARK 900 RELATED ID: 1HK5 RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5' REMARK 900 -TETRAIODO-L- THYRONINE) AND MYRISTIC ACID (TETRADECANOIC ACID) REMARK 900 RELATED ID: 1N5U RELATED DB: PDB REMARK 900 X-RAY STUDY OF HUMAN SERUM ALBUMIN COMPLEXED WITH HEME REMARK 900 RELATED ID: 1O9X RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH TETRADECANOIC ACID (MYRISTIC REMARK 900 ACID) AND HEMIN REMARK 900 RELATED ID: 1TF0 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE GA MODULE COMPLEXED WITH HUMANSERUM ALBUMIN REMARK 900 RELATED ID: 1UOR RELATED DB: PDB REMARK 900 X-RAY STUDY OF RECOMBINANT HUMAN SERUM ALBUMIN. PHASES DETERMINED REMARK 900 BY MOLECULAR REPLACEMENT METHOD, USING LOW RESOLUTION STRUCTURE REMARK 900 MODEL OF TETRAGONAL FORM OF HUMAN SERUM ALBUMIN REMARK 900 RELATED ID: 1YSX RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF DOMAIN 3 FROM HUMAN SERUM ALBUMINCOMPLEXED TO REMARK 900 AN ANTI-APOPTOTIC LIGAND DIRECTED AGAINST BCL-XL AND BCL-2 REMARK 900 RELATED ID: 2BX8 RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH AZAPROPAZONE REMARK 900 RELATED ID: 2BXA RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH 3-CARBOXY-4-METHYL-5-PROPYL-2- REMARK 900 FURANPROPANOIC ACID (CMPF) REMARK 900 RELATED ID: 2BXB RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH OXYPHENBUTAZONE REMARK 900 RELATED ID: 2BXC RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH PHENYLBUTAZONE REMARK 900 RELATED ID: 2BXD RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH WARFARIN REMARK 900 RELATED ID: 2BXE RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH DIFLUNISAL REMARK 900 RELATED ID: 2BXF RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH DIAZEPAM REMARK 900 RELATED ID: 2BXG RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH IBUPROFEN REMARK 900 RELATED ID: 2BXH RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH INDOXYL SULFATE REMARK 900 RELATED ID: 2BXI RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND AZAPROPAZONE REMARK 900 RELATED ID: 2BXK RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE, AZAPROPAZONE AND REMARK 900 INDOMETHACIN REMARK 900 RELATED ID: 2BXL RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND 3,5- REMARK 900 DIIODOSALICYLIC ACID REMARK 900 RELATED ID: 2BXM RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND INDOMETHACIN REMARK 900 RELATED ID: 2BXN RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND IODIPAMIDE REMARK 900 RELATED ID: 2BXO RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND OXYPHENBUTAZONE REMARK 900 RELATED ID: 2BXP RELATED DB: PDB REMARK 900 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND PHENYLBUTAZONE REMARK 999 REMARK 999 SEQUENCE REMARK 999 SEQUENCE CONTAINS SIGNAL AND PRO-PEPTIDE (RESIDUES 1-24 IN REMARK 999 DATABASE ENTRY). PROTEIN CRYSTALLISED WAS THE MATURE REMARK 999 POLYPEPTIDE 25-609 DBREF 2BXQ A 1 585 UNP P02768 ALBU_HUMAN 25 609 SEQADV 2BXQ GLU A 521 UNP P02768 ARG 545 CONFLICT SEQRES 1 A 585 ASP ALA HIS LYS SER GLU VAL ALA HIS ARG PHE LYS ASP SEQRES 2 A 585 LEU GLY GLU GLU ASN PHE LYS ALA LEU VAL LEU ILE ALA SEQRES 3 A 585 PHE ALA GLN TYR LEU GLN GLN CYS PRO PHE GLU ASP HIS SEQRES 4 A 585 VAL LYS LEU VAL ASN GLU VAL THR GLU PHE ALA LYS THR SEQRES 5 A 585 CYS VAL ALA ASP GLU SER ALA GLU ASN CYS ASP LYS SER SEQRES 6 A 585 LEU HIS THR LEU PHE GLY ASP LYS LEU CYS THR VAL ALA SEQRES 7 A 585 THR LEU ARG GLU THR TYR GLY GLU MET ALA ASP CYS CYS SEQRES 8 A 585 ALA LYS GLN GLU PRO GLU ARG ASN GLU CYS PHE LEU GLN SEQRES 9 A 585 HIS LYS ASP ASP ASN PRO ASN LEU PRO ARG LEU VAL ARG SEQRES 10 A 585 PRO GLU VAL ASP VAL MET CYS THR ALA PHE HIS ASP ASN SEQRES 11 A 585 GLU GLU THR PHE LEU LYS LYS TYR LEU TYR GLU ILE ALA SEQRES 12 A 585 ARG ARG HIS PRO TYR PHE TYR ALA PRO GLU LEU LEU PHE SEQRES 13 A 585 PHE ALA LYS ARG TYR LYS ALA ALA PHE THR GLU CYS CYS SEQRES 14 A 585 GLN ALA ALA ASP LYS ALA ALA CYS LEU LEU PRO LYS LEU SEQRES 15 A 585 ASP GLU LEU ARG ASP GLU GLY LYS ALA SER SER ALA LYS SEQRES 16 A 585 GLN ARG LEU LYS CYS ALA SER LEU GLN LYS PHE GLY GLU SEQRES 17 A 585 ARG ALA PHE LYS ALA TRP ALA VAL ALA ARG LEU SER GLN SEQRES 18 A 585 ARG PHE PRO LYS ALA GLU PHE ALA GLU VAL SER LYS LEU SEQRES 19 A 585 VAL THR ASP LEU THR LYS VAL HIS THR GLU CYS CYS HIS SEQRES 20 A 585 GLY ASP LEU LEU GLU CYS ALA ASP ASP ARG ALA ASP LEU SEQRES 21 A 585 ALA LYS TYR ILE CYS GLU ASN GLN ASP SER ILE SER SER SEQRES 22 A 585 LYS LEU LYS GLU CYS CYS GLU LYS PRO LEU LEU GLU LYS SEQRES 23 A 585 SER HIS CYS ILE ALA GLU VAL GLU ASN ASP GLU MET PRO SEQRES 24 A 585 ALA ASP LEU PRO SER LEU ALA ALA ASP PHE VAL GLU SER SEQRES 25 A 585 LYS ASP VAL CYS LYS ASN TYR ALA GLU ALA LYS ASP VAL SEQRES 26 A 585 PHE LEU GLY MET PHE LEU TYR GLU TYR ALA ARG ARG HIS SEQRES 27 A 585 PRO ASP TYR SER VAL VAL LEU LEU LEU ARG LEU ALA LYS SEQRES 28 A 585 THR TYR GLU THR THR LEU GLU LYS CYS CYS ALA ALA ALA SEQRES 29 A 585 ASP PRO HIS GLU CYS TYR ALA LYS VAL PHE ASP GLU PHE SEQRES 30 A 585 LYS PRO LEU VAL GLU GLU PRO GLN ASN LEU ILE LYS GLN SEQRES 31 A 585 ASN CYS GLU LEU PHE GLU GLN LEU GLY GLU TYR LYS PHE SEQRES 32 A 585 GLN ASN ALA LEU LEU VAL ARG TYR THR LYS LYS VAL PRO SEQRES 33 A 585 GLN VAL SER THR PRO THR LEU VAL GLU VAL SER ARG ASN SEQRES 34 A 585 LEU GLY LYS VAL GLY SER LYS CYS CYS LYS HIS PRO GLU SEQRES 35 A 585 ALA LYS ARG MET PRO CYS ALA GLU ASP TYR LEU SER VAL SEQRES 36 A 585 VAL LEU ASN GLN LEU CYS VAL LEU HIS GLU LYS THR PRO SEQRES 37 A 585 VAL SER ASP ARG VAL THR LYS CYS CYS THR GLU SER LEU SEQRES 38 A 585 VAL ASN ARG ARG PRO CYS PHE SER ALA LEU GLU VAL ASP SEQRES 39 A 585 GLU THR TYR VAL PRO LYS GLU PHE ASN ALA GLU THR PHE SEQRES 40 A 585 THR PHE HIS ALA ASP ILE CYS THR LEU SER GLU LYS GLU SEQRES 41 A 585 GLU GLN ILE LYS LYS GLN THR ALA LEU VAL GLU LEU VAL SEQRES 42 A 585 LYS HIS LYS PRO LYS ALA THR LYS GLU GLN LEU LYS ALA SEQRES 43 A 585 VAL MET ASP ASP PHE ALA ALA PHE VAL GLU LYS CYS CYS SEQRES 44 A 585 LYS ALA ASP ASP LYS GLU THR CYS PHE ALA GLU GLU GLY SEQRES 45 A 585 LYS LYS LEU VAL ALA ALA SER GLN ALA ALA LEU GLY LEU HET MYR A1001 16 HET MYR A1002 16 HET MYR A1003 13 HET MYR A1004 13 HET MYR A1005 16 HET MYR A1006 16 HET IMN A2001 25 HET P1Z A2002 23 HET IMN A2003 25 HETNAM MYR MYRISTIC ACID HETNAM IMN INDOMETHACIN HETNAM P1Z 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE FORMUL 2 MYR 6(C14 H28 O2) FORMUL 8 IMN 2(C19 H16 CL N O4) FORMUL 9 P1Z C19 H20 N2 O2 FORMUL 11 HOH *27(H2 O) HELIX 1 1 SER A 5 GLY A 15 1 11 HELIX 2 2 GLY A 15 LEU A 31 1 17 HELIX 3 3 PRO A 35 ASP A 56 1 22 HELIX 4 4 SER A 65 VAL A 77 1 13 HELIX 5 5 THR A 79 GLY A 85 1 7 HELIX 6 6 GLU A 86 LYS A 93 5 8 HELIX 7 7 PRO A 96 LYS A 106 1 11 HELIX 8 8 GLU A 119 ASN A 130 1 12 HELIX 9 9 ASN A 130 HIS A 146 1 17 HELIX 10 10 TYR A 150 CYS A 169 1 20 HELIX 11 11 ASP A 173 PHE A 223 1 51 HELIX 12 12 GLU A 227 GLY A 248 1 22 HELIX 13 13 ASP A 249 ASN A 267 1 19 HELIX 14 14 GLN A 268 ILE A 271 5 4 HELIX 15 15 SER A 272 LYS A 274 5 3 HELIX 16 16 LEU A 275 LYS A 281 1 7 HELIX 17 17 GLU A 285 VAL A 293 1 9 HELIX 18 18 SER A 304 VAL A 310 1 7 HELIX 19 19 ASP A 314 ALA A 322 1 9 HELIX 20 20 ALA A 322 ARG A 336 1 15 HELIX 21 21 SER A 342 CYS A 361 1 20 HELIX 22 22 ASP A 365 ALA A 371 1 7 HELIX 23 23 LYS A 372 LEU A 398 1 27 HELIX 24 24 GLY A 399 VAL A 415 1 17 HELIX 25 25 SER A 419 CYS A 438 1 20 HELIX 26 26 PRO A 441 THR A 467 1 27 HELIX 27 27 SER A 470 GLU A 479 1 10 HELIX 28 28 ASN A 483 ALA A 490 1 8 HELIX 29 29 ALA A 504 THR A 508 5 5 HELIX 30 30 HIS A 510 THR A 515 5 6 HELIX 31 31 SER A 517 LYS A 536 1 20 HELIX 32 32 THR A 540 CYS A 559 1 20 HELIX 33 33 ASP A 563 LEU A 583 1 21 SSBOND 1 CYS A 53 CYS A 62 1555 1555 2.03 SSBOND 2 CYS A 75 CYS A 91 1555 1555 2.03 SSBOND 3 CYS A 90 CYS A 101 1555 1555 2.03 SSBOND 4 CYS A 124 CYS A 169 1555 1555 2.03 SSBOND 5 CYS A 168 CYS A 177 1555 1555 2.02 SSBOND 6 CYS A 200 CYS A 246 1555 1555 2.02 SSBOND 7 CYS A 245 CYS A 253 1555 1555 2.03 SSBOND 8 CYS A 265 CYS A 279 1555 1555 2.03 SSBOND 9 CYS A 278 CYS A 289 1555 1555 2.02 SSBOND 10 CYS A 316 CYS A 361 1555 1555 2.03 SSBOND 11 CYS A 360 CYS A 369 1555 1555 2.04 SSBOND 12 CYS A 392 CYS A 438 1555 1555 2.03 SSBOND 13 CYS A 437 CYS A 448 1555 1555 2.02 SSBOND 14 CYS A 461 CYS A 477 1555 1555 2.03 SSBOND 15 CYS A 476 CYS A 487 1555 1555 2.03 SSBOND 16 CYS A 514 CYS A 559 1555 1555 2.04 SSBOND 17 CYS A 558 CYS A 567 1555 1555 2.03 CISPEP 1 GLU A 95 PRO A 96 0 0.04 SITE 1 AC1 6 ARG A 117 MET A 123 TYR A 138 ALA A 158 SITE 2 AC1 6 TYR A 161 HOH A2010 SITE 1 AC2 6 TYR A 150 ALA A 254 ARG A 257 LEU A 283 SITE 2 AC2 6 SER A 287 HOH A2018 SITE 1 AC3 5 SER A 342 VAL A 344 ARG A 348 ILE A 388 SITE 2 AC3 5 ARG A 485 SITE 1 AC4 4 LEU A 387 TYR A 411 SER A 489 HOH A2026 SITE 1 AC5 7 TYR A 401 ASN A 405 PHE A 507 LYS A 525 SITE 2 AC5 7 MET A 548 PHE A 551 SER A 579 SITE 1 AC6 4 ARG A 209 ASP A 324 LYS A 351 SER A 480 SITE 1 AC7 9 LYS A 199 SER A 202 PHE A 211 TRP A 214 SITE 2 AC7 9 ALA A 215 ARG A 218 LEU A 238 P1Z A2002 SITE 3 AC7 9 HOH A2027 SITE 1 AC8 12 LYS A 199 LEU A 219 ARG A 222 PHE A 223 SITE 2 AC8 12 LEU A 238 HIS A 242 ARG A 257 LEU A 260 SITE 3 AC8 12 SER A 287 ILE A 290 ALA A 291 IMN A2001 SITE 1 AC9 7 ARG A 114 LEU A 115 ARG A 145 HIS A 146 SITE 2 AC9 7 PHE A 157 ARG A 186 LYS A 190 CRYST1 188.250 38.824 95.800 90.00 104.89 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.005312 0.000000 0.001412 0.00000 SCALE2 0.000000 0.025757 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010801 0.00000